AAPB
/ Jiangsu Kanion Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 03, 2025
A novel anti-ischemic stroke candidate drug AAPB with dual effects of neuroprotection and cerebral blood flow improvement.
(PubMed, Acta Pharm Sin B)
- "AAPB significantly reduced cerebral infarction and neural function deficit in tMCAO rats, pMCAO rats, and IS rhesus monkeys, as well as displayed exceptional safety profiles and excellent pharmacokinetic properties in rats and dogs. AAPB has now entered phase I of clinical trials fighting IS in China."
Journal • Cardiovascular • CNS Disorders • Ischemic stroke
1 to 1
Of
1
Go to page
1